Table 1 Baseline characteristics of subjects with T1D and control groups, with subgroups of females and males.
From: Oscillatory pattern of glycemic control in patients with diabetes mellitus
Control | T1D | p value | Distribution F (DFn, DFd) | |||
|---|---|---|---|---|---|---|
Females (n = 22; 78.57%) | Males (n = 6; 21.43%) | Females (n = 65; 45.14%) | Males (n = 79; 54.86%) | |||
Age (years) | 40.17 ± 18.12 | 47.33 ± 19.58 | 34.68 ± 15.42 | 30.72 ± 14.41* | < 0.0001 | (2, 181) = 62.33 |
Weight (kg) | 71.04 ± 7.38 | 68.50 ± 7.01 | 63.49 ± 6.71† | 69.54 ± 13.29 | 0.1785 | (2, 181) = 1.740 |
Height (m) | 169.09 ± 8.95 | 170.50 ± 8.57 | 157 ± 22† | 170 ± 14 | 0.2723 | (2, 181) = 1.310 |
BMI (kg/m2) | 24.86 ± 2.00 | 24.23 ± 1.42 | 24.24 ± 2.48 | 23.74 ± 3.72 | < 0.0001 | (2, 181) = 21.70 |
Duration of diabetes (years) | – | – | 29.48 ± 12.60 | 23.43 ± 11.10 | 0.0267 | (1, 154) = 5.004 |
Treatment (%) | ||||||
Units of insulin per day (U/ml) | – | – | 5.0 ± 1.51 | 5.2 ± 1.9 | 0.36 | |
Rapid acting insulin | ||||||
Aspart | – | – | n = 21 (33.82%) | n = 24 (30.30%) | ||
Lispro | – | – | n = 31 (47.06%) | n = 34(42.42%) | ||
Long-acting insulin | ||||||
Lantus | – | – | n = 47 (73.53%) | n = 55 (69.70%) | ||
Tresiba | – | – | n = 3 (4.41%) | n = 4 (4.55%) | ||
Toujeo | – | – | n = 1 (1.47%) | n = 1 (1.52%) | ||
Levemir | – | – | n = 11 (16.18%) | n = 25 (31.82%) | ||
